Biodesix, Inc. (BDSX) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin Including Sales and Use Tax Recovery | 84.00 percent | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | -4.05M | FY2026-Q1 |
| Lung Diagnostic Test Revenue | 22.29M | FY2026-Q1 |
| Operating Expense Excluding Direct Costs and Expenses | 27.6M | FY2026-Q1 |
| Development Services Revenue | 3.26M | FY2026-Q1 |
| Development Services Dollars Under Contract | 12.9M | FY2025-Q3 |
Back to BDSX overview · BDSX earnings · BDSX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.